NOT FOR DISTRIBUTION
Header cover image

Jilin Province Huinan Changlong Bio-pharmacy

Market Cap

HK$700.3m

Last Updated

2021/04/17 10:20 UTC

Data Sources

Company Financials

Executive Summary

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Jilin Province Huinan Changlong Bio-pharmacy's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8049 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 8049's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-1.6%

8049

-1.5%

HK Pharmaceuticals

0.7%

HK Market


1 Year Return

-3.1%

8049

18.8%

HK Pharmaceuticals

28.0%

HK Market

Return vs Industry: 8049 underperformed the Hong Kong Pharmaceuticals industry which returned 18.8% over the past year.

Return vs Market: 8049 underperformed the Hong Kong Market which returned 28% over the past year.


Shareholder returns

8049IndustryMarket
7 Day-1.6%-1.5%0.7%
30 Day4.2%-4.6%-1.2%
90 Day6.8%6.2%1.8%
1 Year-0.9%-3.1%20.5%18.8%33.4%28.0%
3 Year-1.2%-15.5%-11.0%-16.0%8.1%-3.9%
5 Year-13.0%-25.6%94.1%75.5%56.5%28.9%

Long-Term Price Volatility Vs. Market

How volatile is Jilin Province Huinan Changlong Bio-pharmacy's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jilin Province Huinan Changlong Bio-pharmacy undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 8049 (HK$1.25) is trading below our estimate of fair value (HK$5.01)

Significantly Below Fair Value: 8049 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 8049 is good value based on its PE Ratio (4.6x) compared to the HK Pharmaceuticals industry average (12.6x).

PE vs Market: 8049 is good value based on its PE Ratio (4.6x) compared to the Hong Kong market (11.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8049's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8049 is good value based on its PB Ratio (0.4x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is Jilin Province Huinan Changlong Bio-pharmacy forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jilin Province Huinan Changlong Bio-pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Jilin Province Huinan Changlong Bio-pharmacy performed over the past 5 years?

3.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8049 has high quality earnings.

Growing Profit Margin: 8049's current net profit margins (20.3%) are lower than last year (22.4%).


Past Earnings Growth Analysis

Earnings Trend: 8049's earnings have grown by 3% per year over the past 5 years.

Accelerating Growth: 8049's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 8049 had negative earnings growth (-12.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).


Return on Equity

High ROE: 8049's Return on Equity (9.4%) is considered low.


Financial Health

How is Jilin Province Huinan Changlong Bio-pharmacy's financial position?


Financial Position Analysis

Short Term Liabilities: 8049's short term assets (CN¥807.9M) exceed its short term liabilities (CN¥415.4M).

Long Term Liabilities: 8049's short term assets (CN¥807.9M) exceed its long term liabilities (CN¥43.6M).


Debt to Equity History and Analysis

Debt Level: 8049's debt to equity ratio (0.03%) is considered satisfactory.

Reducing Debt: 8049's debt to equity ratio has reduced from 1% to 0.03% over the past 5 years.

Debt Coverage: 8049's debt is well covered by operating cash flow (37806.8%).

Interest Coverage: 8049 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Jilin Province Huinan Changlong Bio-pharmacy current dividend yield, its reliability and sustainability?

3.34%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 8049's dividend (3.34%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.93%).

High Dividend: 8049's dividend (3.34%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: 8049 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 8049 has only been paying a dividend for 2 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.0yrs

Average management tenure


CEO

Hong Zhang (65 yo)

no data

Tenure

CN¥526,000

Compensation

Mr. Hong Zhang serves as the Chief Executive Officer and Compliance Officer at Jilin Province Huinan Changlong Bio-pharmacy Co. Ltd. and has been its Executive Chairman since October 1989. Mr. Zhang is res...


CEO Compensation Analysis

Compensation vs Market: Hong's total compensation ($USD80.67K) is below average for companies of similar size in the Hong Kong market ($USD227.72K).

Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 8049's management team is seasoned and experienced (13 years average tenure).


Board Members

Experienced Board: 8049's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jilin Province Huinan Changlong Bio-pharmacy Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jilin Province Huinan Changlong Bio-pharmacy Company Limited
  • Ticker: 8049
  • Exchange: SEHK
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$700.314m
  • Shares outstanding: 560.25m
  • Website: https://www.jlchanglong.com

Number of Employees


Location

  • Jilin Province Huinan Changlong Bio-pharmacy Company Limited
  • 31 Beishan Street
  • Pharmaceutical Industrial Park
  • Tonghua
  • Jilin Province
  • 135100
  • China

Listings


Biography

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. It offers tablet...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 10:20
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.